Excipients (Suspending Agents)

Usually inert substances added to a prescription in order to provide suitable consistency to the dosage form. These include binders, matrix, base or diluent in pills, tablets, creams, salves, etc.

Also Known As:

Networked: 1110 relevant articles (67 outcomes, 112 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Smith, Amos B: 11 articles (01/2018 - 03/2005)
2.	Miller, John H: 11 articles (12/2017 - 03/2007)
3.	Northcote, Peter T: 11 articles (12/2017 - 03/2007)
4.	Ballatore, Carlo: 8 articles (09/2017 - 08/2012)
5.	Brunden, Kurt R: 8 articles (09/2017 - 08/2012)
6.	Trojanowski, John Q: 8 articles (09/2017 - 08/2012)
7.	Lee, Virginia M-Y: 7 articles (09/2017 - 08/2012)
8.	Horwitz, Susan Band: 6 articles (01/2018 - 04/2002)
9.	Laffleur, Flavia: 5 articles (06/2019 - 02/2017)
10.	Paterson, Ian: 5 articles (12/2017 - 08/2010)

Related Diseases

1.	Neoplasms (Cancer) 09/10/2013 - "Such an expansion in the excipient capacity arises from (i) the increased drug retention of submicellar assemblies due to their higher resistance to dilution and therefore to their improved circulation time and (ii) the superior carrier permeability of these premicellar aggregates as a result of their smaller size, which makes these drug vehicles more effectively targeted to the tumors through the so-called enhanced permeability and retention effect. " 10/01/2021 - "Not only that, DP-HICT NRs can escape the clearance of the immune system and enhance targeting ability to the tumor site with only one excipient and such a low dose. " 01/01/2023 - "This opens the window of new applications for microtubule-stabilizing agents beyond cancer treatment." 01/01/2021 - "A novel furan-2-carboxamide based small molecule, is a selective microtubule stabilizing agent (MSA) with IC50 ranging from 4 µM to 8 µM in different cancer cell lines. " 01/01/2021 - "Furan-2-carboxamide derivative, a novel microtubule stabilizing agent induces mitotic arrest and potentiates apoptosis in cancer cells."
2.	Bipolar Disorder (Manic Depressive Psychosis) 12/01/2006 - "Studies of TPM in bipolar disorder are evaluated, and the efficacy and tolerability issues as a mood stabilizing agent are discussed." 08/01/2004 - "Further studies are needed on gestational timing and exposure to mood-stabilizing agents, especially newer agents recently approved or currently being considered for the treatment of bipolar disorder." 01/01/2023 - "Bipolar disorder (BPD) is associated with high rates of suicide attempts but the anti-suicidal effect of mood stabilizing agents remains unclear. " 01/01/2021 - "iTBS targeting the LDLPFC is not efficacious in the treatment of acute bipolar depression in patients receiving antimanic or mood stabilizing agents. " 06/01/2005 - "The use of at least one mood-stabilizing agent is common clinical practice in the treatment of bipolar disorder, regardless of the treatment setting or disease phase. "
3.	Hypersensitivity (Allergy) 09/01/2008 - "Once informed of a patient's allergy, intolerance, or special diet, the compounding pharmacist is able to prepare a prescription from which a particular excipient has been eliminated. " 01/11/2021 - "6. Any known hypersensitivity to any of the ingredients, or excipients of the study medication, BIO101. " 04/01/2020 - "The aim of this study was to review the literature on allergy to pharmaceutical excipients and to record the IHRs described with various types of medications, specifically reactions due to the excipients contained in their formulations. " 01/01/2020 - "The aim of this study was to perform a literature review on allergy to pharmaceutical excipients and to record the DHRs described with various types of medications, specifically due to the excipients contained in their formulations. " 11/01/2016 - "The aim of this study was to give an overview of the prevalence of contact allergy to active ingredients and excipients of topical medications across Europe. "
4.	Breast Neoplasms (Breast Cancer) 11/19/2021 - "While Mito-Esc itself induces selective breast cancer cell death, the amphiphilic nature of Mito-Esc delivers therapeutic siRNAs intracellularly without the need for any excipient to exacerbate the anti-proliferative effects." 04/01/2012 - "Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents." 08/26/2020 - "The generation of pure nanodrugs via a self-assembly approach might hold promise for the development of more efficient and novel excipient-free nanodispersions, particularly for two small molecular antitumor drugs that potentially exert synergistic antiproliferative effects on metastatic breast cancer." 01/01/2020 - "Interactions of Oral Molecular Excipients with Breast Cancer Resistance Protein, BCRP." 01/01/2019 - "Paclitaxel (PTX) is a microtubule-stabilizing agent widely used to treat breast cancer. "
5.	Infections 06/01/2019 - "The aim of this study was to synthesize novel polymeric excipients forming mucoadhesive films for treatment of vaginal microbial infections. " 01/01/2022 - "Fluorescence microscopy revealed QP188 accumulation in fibroblast mitochondria, suggesting that the excipient may modulate mitochondrial processes relevant to CMV infection. " 11/18/2010 - "Twelve hours after exposure to the excipient or a control treatment, mice were challenged with a vaginal dose of HSV-2, and three days later were assessed for infection by vaginal lavage culture to assess susceptibility. " 07/01/2001 - "The negative controls, infection of mice with 100 LD(50) of EMCV followed by treatment with excipient via all three routes, resulted in death of nearly all mice, as expected. " 08/01/1999 - "Five cows were subcutaneously treated with 500 mg of recombinant bST 7 d before and after infection, and 5 control cows received the excipient. "

Related Drugs and Biologics

1.	Paclitaxel (Taxol)
2.	Lithium
3.	Tablets
4.	Polymers
5.	Vaccines
6.	Epothilones (Epothilone)
7.	Sucrose (Saccharose)
8.	Cromolyn Sodium (Cromoglicic Acid)
9.	Cyclodextrins
10.	Therapeutic Uses

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Craniotomy
3.	Therapeutics
4.	Injections
5.	Aftercare (After-Treatment)